Spondyloarthropathies

John Flynn, M.D.

Abstract #756: Impact of Infliximab on Costs of Ankylosing Spondylitis: Results of Eres Study, and Economic Evaluation Based on One-Year Randomized Controlled Trial in a One-Year Open-Label Extension Study

Abstract #2017: Treatment With Adalimumab Reduces Signs and Symptoms and Induces Partial Remission in Patients With Ankylosing Spondylitis (AS): One-Year Results From ATLAS.

Abstract #1116: Efficacy of Lower Dose Infliximab in Active Ankylosing Spondylitis: Interim Results of a Canadian Study

Abstract #1115: New Biomarkers in Monitoring Disease Activity in Ankylosing Spondylitis and Psoriatic Arthritis Patients Treated with TNF-a Inhibitors

Abstract #2016: Comparison of the Effect of Infliximab on Inflammation and Bone Formation Biomarkers and Association With Clinical Response in Ankylosing Spondylitis and Psoriatic Arthritis

Abstract #2021: CASPAR Criteria Are Sensitive in Early Psoriatic Arthritis

Abstract #2058: The Relationship Between the Extensor Tendon Enthesis and Distal Interphalangeal Joint Disease in Psoriatic Arthritis: High-Resolution MRI and Histological Study

Abstract #199: The Role of MRI Imaging in the Diagnosis of Early Inflammatory Back Pain